Pair Name | Astragaloside IV, Bevacizumab | ||
Phytochemical Name | Astragaloside IV (PubChem CID: 13943297 ) | ||
Anticancer drug Name | Bevacizumab (PubChem CID: / ) | ||
Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
Pair Name | Astragaloside IV, Bevacizumab | |||
Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Up-regulation | Phosphorylation | AKT1 | hsa207 |
Up-regulation | Expression | BAX | hsa581 | |
Down-regulation | Expression | BCL2 | hsa596 | |
Down-regulation | Expression | BECN1 | hsa8678 | |
Up-regulation | Cleavage | CASP3 | hsa836 | |
Up-regulation | Phosphorylation | MTOR | hsa2475 | |
Up-regulation | Expression | SQSTM1 | hsa8878 | |
In Vitro Model | A-549 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_0023 |
Result | This paper demonstrates that AST-IV enhances the effect of BV on inhibiting proliferation and promoting apoptosis of lung adenocarcinoma cells through inhibiting autophagy pathway. |
No. | Title | Href |
---|---|---|
1 | Astragaloside IV enhances the sensibility of lung adenocarcinoma cells to bevacizumab by inhibiting autophagy. Drug Dev Res. 2022 Apr;83(2):461-469. doi: 10.1002/ddr.21878. | Click |